Biogen Inc. (NASDAQ:BIIB) and Eisai Ltd’s (OTC:ESALY) Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure.
For many, like Mississippi English professor Missie Meeks, the treatment is helping to slow the progression of Alzheimer’s, allowing her to maintain independence in daily life.
Also Read: Biogen’s Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder.
Meeks, who was diagnosed with Alzheimer’s ahead of her 50th birthday, has been receiving biweekly infusions of Leqembi since September 2023, giving her more time to function independently, even if the treatment hasn’t eliminated her cognitive struggles.
Leqembi, a monoclonal antibody, moderately slows memory and cognitive decline in ...
